Since these kinases are key downstream effectors of oncogenic KRAS which by itself is a main driver of PDAC development, progression, and metastasis, the targeting of ERK1/2 turns E260 into a unique and potent anti-cancer compound that in parralel, targets several regulatory arms which are essential for PDAC tumors development and progression (37, 43). The gene discussed is MAPK3; the disease is cancer.